2016 2016 - JADPRO
 

JADPRO Live 2016 Accredited Educational Activities

Earn CE credit with these accredited educational activities based on presentations from JADPRO Live at APSHO 2016. Access the full-length video presentation, the slide deck, transcript, and the entire lecture as a podcast. You can earn CE for each of these activities by following the links.

Click on any of the video presentations below to get started!

Pancreatic  |  Immunotherapy  |  Multiple Myeloma  |  VTE  |  Gastric Cancer  |  Skin  |  Infectious Complications  |  Lung  |  Head and Neck  |  Breast  |  CAR-T  |  Aggressive Lymphomas  |  CLL  |  CINV
What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer

This activity is supported by an educational grant from Celgene and Merrimack Pharmaceuticals, Inc.

Pancreatic

What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer

Pancreatic cancer is known to carry a poor prognosis. Only 15%–20% of patients present with potentially resectable disease, and therefore accurate diagnosis and staging is essential. It is also important that providers are aware of emerging data and guidelines regarding second- and third-line treatment options. This educational activity will provide the advanced practitioner with important information regarding risk assessment, diagnostic workup, treatment considerations (including surgery, radiation, and chemotherapy), and supportive care.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Immunotherapy Advances and Updates

This activity is supported by an educational grant from Merck & Co.

Immunotherapy

Immunotherapy: Advances and Updates

One of the greatest advances in oncology over the past decade has been the recognition of cell surface proteins that are shown to play a key role in tumor immunogenicity; mechanisms in which tumors are able to avoid immune surveillance and destruction. Although immunotherapy is a relatively new approach to anti-cancer treatment, it is being utilized across multiple tumor types. This program highlights the science behind immunotherapy, immune-related adverse side effects (irAEs), monitoring and managing irAEs, the role of biomarkers, and differentiating pseudo-progression from actual disease progression.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma

This activity is supported by an educational grant from Celgene and Takeda Oncology.

Multiple Myeloma

New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma

Despite the fact that multiple myeloma remains incurable, mean overall survival has improved dramatically as newer game-changing therapies enter the scene. At the same time, treatment decisions are becoming more complex. This educational activity provides indispensable information regarding risk categories, mechanisms of action for newer drugs, appropriate therapeutic options and sequencing, including identification of transplant eligible patients, and the management of toxicities related to newer drug regimens, thus equipping advanced practitioners to provide optimum clinical support for their patients throughout the trajectory of their disease. 

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Management of Venous Thromboembolism for Patients with Hematologic Malignancies

This activity is supported by an educational grant from Celgene.

VTE

Management of Venous Thromboembolism for Patients with Hematologic Malignancies

Advanced practitioners (APs) are an integral part of the cancer care team. Therefore, it is imperative they are knowledgeable of risk factors associated with venous thromboembolism (VTE) in the oncology setting, including signs or symptoms and management. Early intervention is crucial. APs must also be able to differentiate between anticoagulation drugs and select the appropriate treatment for their patient with VTE. This educational program will provide the AP with an overview of VTE risks in cancer patients, indications and contraindications for prophylaxis or treatment, antidotes/reversal agents, and patient monitoring.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 0.75

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Collaborative Management of Patients with Gastric Cancer

This activity is supported by an unrestricted educational grant from Bristol-Myers Squibb, Lilly USA, LLC, and Merck & Co.

Gastric Cancer

Collaborative Management of Patients with Gastric Cancer

Advanced gastric and esophageal cancers are associated with poor outcomes. However, as knowledge of disease biology improves, treatment options are increasing. Genomic profiling has identified targetable mutations or biomarkers, such as HER2. Immunotherapies such as checkpoint inhibitors may be approved for gastrointestinal malignancies in the very near future. This program provides an overview of clinical trials, new treatment options, as well as practical clinical information regarding diagnosis, staging, monitoring, and managing side effects to treatment, in order to ameliorate clinical confidence and patient outcomes.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Management of Patients with Skin Cancers Basal Cell Carcinoma and Melanoma

This activity is supported by an educational grant from Bristol-Myers Squibb and Merck & Co, Inc.

Skin

Management of Patients with Skin Cancers: Basal Cell Carcinoma and Melanoma

Novel, cutting-edge therapies are changing the treatment paradigm for both melanoma and advanced/metastatic basal cell carcinoma. While immunotherapies are increasing survival benefits in melanoma, they are associated with unique, potentially severe or even lethal immune-related adverse events (irAEs). Many advanced practitioners lack familiarity with newer immunotherapies and hedgehog inhibitors. This learning activity will equip APs with the knowledge needed to provide safe, state-of-the-art care for their patients with melanoma or basal cell skin cancer.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 0.75

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Best Practices in the Management of Infectious Complications for Patients with Cancer

This activity is supported by an independent medical educational grant from Sandoz Inc., a Novartis Company.

Infectious Complications

Best Practices in the Management of Infectious Complications for Patients with Cancer

Immune suppression increases the risk for developing infection and/or sepsis. As antibiotic resistant bacteria are becoming ubiquitous, managing infection becomes more complex. Optimizing preventive measures, early diagnosis and management of infection is of the highest priority in cancer care. This educational activity will enable advanced practitioners to hone their skills in risk assessment, recognition and early intervention in the management of infection, optimizing treatment in the era of antibiotic-resistant bacteria, and understand the role of biosimilars and their reference G-CSFs in the prophylaxis and treatment of febrile neutropenia.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 0.75

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinoma of the Lung

This activity is supported by an educational grant from AstraZeneca, Bristol-Myers Squibb, Celgene, Lilly, and Merck.

Lung

Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinoma of the Lung

Following years in which there were only modest gains in treatment options for non–small cell lung cancer, the number of drugs approved in the past 5 years is unprecedented. Recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions. This educational activity will provide the advanced practitioner with updates on the latest research, current guidelines in the diagnosis and workup, as well as information on novel treatments and side effect management to ensure the best outcomes for patients with NSCLC.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Advances in Collaborative Practice for Patients with Head and Neck Cancers

This activity is supported by an educational grant from Bristol-Myers Squibb.

Head and Neck

Advances in Collaborative Practice for Patients with Head and Neck Cancers

Head and neck cancer care is complex, and there are limited treatment options; over the past decade only one new therapy received FDA approval. However, as in other tumor types, the landscape is changing with the recent emergence of newer targeted therapies and immunotherapies. This learning activity will provide advanced practitioners with valuable updates on screening and prevention, the risk associated with human papillomavirus (HPV), treatment options, mechanisms of action for new therapies, and monitoring for and the management of adverse events.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer

This activity is supported by an educational grant from Lilly and Merck.

Breast

Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer

The standard treatment approach for ER+ breast cancer includes surgery, radiation, or both, along with chemotherapy, endocrine therapy, targeted therapy, or combinations of these approaches. Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. The major side effect is hematologic toxicity, however, this differs from the hematologic effects associated with conventional cytotoxic chemotherapy. This educational program will provide advanced practitioners valuable insight into the science behind CDK inhibition, when CDKs are indicated, how to monitor for and manage side effects, as well as when and how to dose adjust.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Understanding the Mechanism of Action for Chimeric Antigen Receptor Therapy

This activity is supported by an educational grant from Genentech.

CAR-T

Understanding the Mechanism of Action for Chimeric Antigen Receptor (CAR) Therapy

Adoptive immunotherapy involves engineering the patient’s own T-cells by artificially equipping them with chimeric antigen receptors (CARs) which then enable them to bind to certain proteins on the surface of malignant cells. Referred to as CAR-T cell therapy, this form of treatment has had stunning results in acute lymphoblastic leukemia (ALL) and lymphoma. Cytokine release syndrome (CRS), which can be severe and involve multi-organ failure, is a major potential toxicity. This program will provide advanced practitioners with cutting edge information about adoptive CAR-T cell immunotherapy, mechanism of action, unique and potentially serious side effects, and how to monitor for and manage CRS.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Nuances in the Management of Aggressive Lymphomas

This activity is supported by an educational grant from Genentech.

Aggressive Lymphomas

Nuances in the Management of Aggressive Lymphomas

Treatment for both Hodgkin and non-Hodgkin’s lymphoma now includes chemotherapy, targeted therapy, and new immunotherapies. As research continues to shine the light on tumor genetics, clinical variability, and new treatment approaches, advanced practitioners (APs) need to translate this information to the bedside in the management of aggressive lymphomas. This educational activity will provide APs with the latest update on emerging treatments for aggressive, relapsed/refractory lymphomas, as well as potential adverse events and how to manage them, with the goal of optimizing treatment effectiveness and patient outcomes.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Defining the New Treatment Paradigm for Patients with Chronic Lymphocytic Leukemia

This activity is supported by an educational grant from AbbVie, Celgene, Genentech, and Gilead.

CLL

Defining the New Treatment Paradigm for Patients with Chronic Lymphocytic Leukemia

Oncology care is undergoing dynamic changes across tumor types with novel therapies being developed at a rapid pace. Within the past 3 years, the FDA has approved five new treatment options for patients with CLL. While these advances improve patient outcomes and the quality of care, the need for advanced practitioners (APs) to stay up to date and informed in order to translate these advances into the clinical setting is daunting. This educational activity will provide APs with important information on the diagnostic workup, risk assessment/prognostic indicators, optimizing treatment selection, response monitoring, mechanism of actions, and side effect management of newer therapies.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

Management of Patients with Chemotherapy Induced Nausea and Vomiting

This activity is supported by an educational grant from Genentech.

CINV

Management of Patients with Chemotherapy - Induced Nausea and Vomiting

The first 5-HT3 antagonist was approved in 1991 for the management of chemotherapy-induced nausea and vomiting (CINV), leading to moving more chemotherapy regimens to the outpatient setting and improving adherence to treatment. Since then, several 5-HT3 antagonists and NK-1 receptor antagonists have been added to the armamentarium. Despite advances, CINV is often inadequately prevented and/or managed. This learning activity reviews current evidence-based interventions for the prevention and management of CINV, including physiologic mechanisms associated with CINV, strategies to target the pathways involved in CINV, and recommended guidelines.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 0.75

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

These CE/CME/CEU accredited activities are jointly provided by

JADPRO Logo    Harborside Press Logo    APSHO Logo    Annenberg Logo

These CE/CME/CEU accredited activities are jointly provided by

JADPRO Logo    Harborside Press Logo    APSHO Logo    Annenberg Logo
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me